Brief: Atea Pharmaceuticals Announces First Patient Dosed In Phase 2 Study For Treatment Of Hepatitis C
15/06/2023 12:08
June 15 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 2
STUDY FOR TREATMENT OF HEPATITIS C WITH BEMNIFOSBUVIR AND
RUZASVIR COMBINATION
* ATEA PHARMACEUTICALS INC - PRELIMINARY DATA FROM 60
PATIENT
LEAD-IN COHORT ARE ANTICIPATED IN Q4 OF 2023
Source text for Eikon: ID:nGNX5gxt5F
Further company coverage: AVIR.O
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM